I
nflammatory bowel disease (IBD) is a complex chronic condition that affects approximately 1 million Americans. 1 The combination of chronicity and early onset makes IBD a disease with high morbidity. 2 In addition, the societal costs are significant for young working individuals who struggle with IBD. 3 The insights into the pathophysiology of IBD and available therapeutics continue to grow at an exponential rate. However, the medium in which we communicate with and take care of patients with IBD has not evolved at the same pace.
Telemedicine encompasses a broad range of services including telemonitoring (e.g., wearables and mobile devices), teleconsultation, (e.g., remote intensive care unit management), and telecare. 4 Telecare uses some method of video interaction to create a virtual face-to-face visit. Although telemedicine may be inappropriate for patients with IBD with a new onset of symptoms or emergent problems where physical examination is required, virtual visits may be an excellent alternative as part of their chronic disease management.
Value of health care can be expressed as the formula of quality divided by cost. If we can maintain or increase quality while decreasing cost, we have an opportunity to increase overall value. Telemedicine may offer patients a convenient, low-cost, and high-quality alternative to see their physicians in office for routine follow-up care. Thus, we hypothesize that telemedicine in the form of telecare will increase value while achieving high satisfaction for patients with IBD.
MATERIALS AND METHODS

Telemedicine Visits
At Dartmouth-Hitchcock Medical Center, telemedicine visits are performed using any device connected to the internet with a camera along with Virtual Visit and VidyoDesktop software. Links are sent to patients by the visit secretary, and patients are encouraged to do a test call before their appointment. Patients were given a reminder before the visit with either a telephone call or mailed letter. Before each visit, patients take a previsit survey that asks about their current disease state including quality outcome measures. The visit itself is attended by the patient and the IBD specialist with or without an IBD nurse. After the visit, the patient fills out a postvisit survey that includes questions about the patient's experience of the visit, time and money saved by not driving to the appointment, and preference for future visits.
Assessment of Quality Outcome Measures
Consecutive patients participating in the IBD telemedicine clinic at Dartmouth-Hitchcock Medical Center in the second half of 2015 were included. A single IBD provider was involved for every visit (CAS). Exclusion criteria included patients whose workup did not result in diagnosis of IBD and patients who were lost to followup. Data regarding patient's perceived quality of care along with IBD quality outcome measures were extracted from survey results and patient charts. Baseline characteristics recorded were age, sex, type of IBD (ulcerative colitis or Crohn's disease), duration of disease, and previous surgery. Survey results for each telemedicine visit were compiled and summarized using simple descriptive statistics. A before and after study design was used such that IBD quality outcome measures were collected for patients in the year before participating in telemedicine visits and for the year after participation. These quality outcome measures included steroid use, number of days in the hospital for IBD, number of emergency department visits for IBD, number of routine follow-up visits for IBD, narcotics use, incontinence, nighttime bowel movements, and current biologics therapy exposure. 5 Outcome measures before and after the implementation of telemedicine visits were compared using odds ratios (ORs). Fisher's exact test was used to assess statistical significance of differences in outcome. Two-sided statistical significance was defined as P , 0.05. All statistical analyses were performed using Stata 13.1. This project was reviewed and approved by the Committee for Protection of Human Subjects at Dartmouth College.
RESULTS
Fifty-three patients participated in telemedicine visits in the second half of 2015. Of the 53 patients, 48 fit inclusion criteria (3 were lost to follow-up and 2 were not diagnosed with IBD). Baseline characteristics of this patient cohort are summarized in Table 1 . Patient out-of-pocket and opportunity costs are summarized in Figure 1 . Eighty-one percent of patients who participated in telemedicine clinic lived more than 25 miles away from their provider. In addition, patients reported a wide range of travel costs for an in-office appointment, with an average cost of $62 (range: less than $50 to more than $200). Patients typically saved between a half day and full day of time by taking part in televisits as compared with in-person visits. Ninety-six percent of patients reported that the audio-visual quality of the visit was adequate for a meaningful discussion during the visit. Ninety-eight percent of patients reported that the time allotted for a telemedicine visit was adequate. In addition, 91% of patients perceived that their physician understood their disease state and 78% reported that they clearly understood the follow-up plan after the visit. Last, 77% of patients who participated in our telemedicine clinic continued to use telemedicine as the preferred method of follow-up.
IBD quality outcome measures before and after starting telemedicine are reported in Table 2 and Figure 2 . There were no differences in current steroid use (25% versus 15%; OR ¼ 0.51, P ¼ 0.21) or current biologic therapy exposure (71% versus 77%; OR ¼ 1.39, P ¼ 0.49) before and after the implementation of telemedicine clinics. The OR for changes in narcotic use, health care utilization, and symptoms was also not statistically significant.
DISCUSSION
This study highlights the feasibility and sustainability of using telemedicine visits for the outpatient care of a patient with IBD. Without a decrement in quality of care, but with decreased costs to patients, these results support the hypothesis that telemedicine can increase the value of IBD care delivered.
Almost all patients had a good experience with telemedicine visits as measured by the audio-video performance and that patients felt like the physician understood their disease state and enough time was allotted for the appointment. Most patients reported that they clearly understood the follow-up plan and preferred to do their next visit as a telemedicine visit. This patient-reported metric is reinforced by the fact that 77% of patients continued to use telemedicine as their method of follow-up.
The telemedicine clinic allowed patients to save on average $62 of out-of-pocket costs. In addition to direct savings, reduced out-of-pocket payment has been associated with other positive health outcomes such as increased medicine adherence. 6 Streamlining IBD care delivery can keep many of the young working patients at work instead of away from work to have an in-office visit. Thus, it is conceivable that the economic impact of cost reduction for telemedicine reaches further than what this study directly reports.
The average age of the study population is 42 years, which is consistent with population studies in IBD. It is possible that the young patient population is more likely to engage in telemedicine, but we highlight that the range of ages in our study population is large and our oldest patient is 76 years. The disease characteristics are heterogeneous with 71% Crohn's disease and 29% ulcerative colitis with an average disease duration of 12.7 years. Thirty-one percent (31%) of patients have previously undergone bowel resection. It is evident that our study population, albeit small and with 1 provider, spans the spectrum of disease severity and control.
There were no significant differences in quality of care based on the quality outcome metrics assessed from before and after participating in the telemedicine clinic. Although it is possible that further systematic use of telemedicine clinics could increase quality of care by increasing access to follow-up, the fact that there was no decrease in quality when patients shifted to these clinics is in itself a success. If we can decrease the cost of care for patients while maintaining high quality, then we have increased the value of their care.
The field of IBD is leveraging telemedicine technology more, as the technology becomes readily available. Many of these efforts focus on remote monitoring of the patient's disease state. A group in Denmark has successfully implemented the constant care approach, where telemonitoring of disease severity led to timely intervention and improved clinical outcomes. [7] [8] [9] Similarly, Project Sonar from the Illinois Gastroenterology Group and Blue Cross Blue Shield of Illinois successfully developed a patient facing web-based platform, where patients can self-report symptoms. Based on the reported symptoms, patients are risk stratified, and IBD care is catered accordingly. 10 Dr. Ray Cross at the University of Maryland has led a telemedicine program for IBD for a number of years focused on telemonitoring. This group has shown that disease-specific quality of life can be improved using this technology. 11, 12 Our study is unique in that the objective is to study the value of care delivered. When the patient costs in addition to the quality of care are considered, we can develop more patientcentered, efficient, and socially responsible care delivery models.
There are limitations to this study regarding both patient selection and methodology of review. Although our patient population is diverse in demographics, patient selection favored patients known to a single provider thus introducing possible selection bias. Although we did not systematically capture disease activity at each visit, using medication use as a surrogate, there were no differences between steroid and biologic use before and after implementation of telemedicine clinic. It is possible that the retrospective chart review to evaluate health care utilization after the switch to telemedicine could have missed important clinical events including disease flares or complications. The quality outcomes should be interpreted with caution. Although we used quality metrics that have been published by the American Gastroenterological Association (AGA) and the Crohn's and Colitis Foundation, the metrics have not been validated prospectively to prove that they are associated with better long-term patient outcomes. In addition, the quality outcomes looked very similar before and after the intervention, but we were underpowered to detect small differences. To properly study the impact on long-term quality of care, a well-powered, large noninferiority study of likely hundreds of patients would be required to answer this question.
Although televisits in this study were conducted in a research setting, we highlight some of the barriers to implement telemedicine clinics in practice. Reimbursement continues to be an issue with regulatory restrictions on originating site (where patients can call from) and inconsistent reimbursement parity from insurance companies. Also, because telemedicine allows 4 The telemedicine program at the Dartmouth-Hitchcock IBD Center was able to demonstrate that virtual visits can be used to provide a low-cost and convenient method for the delivery of care without compromising quality. Further studies are needed with a broader patient population and longer systematic follow-up, but the concept of increasing the value of care using telemedicine for patients with IBD has significant promise. We hope to encourage others to examine the usefulness of telemedicine in their practice and together identify common successes and barriers so that IBD telehealth can be spread to a broader audience.
